Refined risk stratification helps guiding transplantation choice in adult BCR::ABL1-positive acute lymphoblastic leukemia

作者：Cheng Wang, Jianfeng Li, Weiyang Liu, Lingling Zhao, Han Yan, Yuchen Yan, Jiayi Ren, Lijun Peng, Jiaojiao Zhang, Yuanfang Liu, Xiangqin Weng, Yongmei Zhu, Duohui Jing, Jian‐Qing Mi, Jin Wang · 发表于：Blood Cancer Journal · 年份：2024 · DOI：10.1038/s41408-024-01055-1 · 被引用次数：8 · 研究领域：Acute Lymphoblastic Leukemia research、Chronic Myeloid Leukemia Treatments、Acute Myeloid Leukemia Research

The integration of tyrosine kinase inhibitors (TKIs) into multiagent chemotherapy regimens has markedly improved the prognosis of BCR::ABL1 -positive acute lymphoblastic leukemia ( BCR::ABL1 + ALL). Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a backbone of contemporary curative treatments for adult BCR::ABL1 + ALL.